Other News

Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results

SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of […]

Life Line Screening, Nationwide Cardiovascular Health & Stroke Risk Screening Company, Announces Amanda Rangel as Senior Vice President of Global Business Solutions

AUSTIN, Texas–(BUSINESS WIRE)–Life Line Screening, the nation’s leading provider of mobile preventive health screenings for cardiovascular disease and stroke risk is pleased to announce the appointment of Amanda Rangel as Senior Vice President of Global Business Solutions. With her rich background in fostering corporate relationships, Amanda’s expertise will be instrumental as Life Line Screening broadens its commercial outreach. Amanda Rangel comments on her new role: “I’m thrilled to join L

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February […]

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: […]

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently […]

RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024

SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced the publication of the TIMELESS trial in the New England Journal of Medicine (NEJM). Other select data from research studies unveiled last week at the […]

Canary Completes First-in-Human Trial of Cardiac Auscultation Monitoring Sensor

The Cardiac Auscultation monitoring device was trialed for use with heart failure patients as an adjunct to care in monitoring the effectiveness of congestive heart failure medication management The limited clinical trial represents the first human implantation of a cardiac auscultation sensor device Heart failure affects one in five people, […]

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all five evaluable patients Cardiac biopsies were obtained from a patient at week 6 and 24 and showed robust and durable delivery, transgene expression and […]